# A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia

> **NCT02688764** · PHASE3 · TERMINATED · sponsor: **Vifor Fresenius Medical Care Renal Pharma** · enrollment: 85 (actual)

## Conditions studied

- Hyperphosphatemia

## Interventions

- **DRUG:** PA21 (Velphoro®)
- **DRUG:** Calcium Acetate (Phoslyra®)

## Key facts

- **NCT ID:** NCT02688764
- **Lead sponsor:** Vifor Fresenius Medical Care Renal Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-26
- **Primary completion:** 2019-02-21
- **Final completion:** 2019-02-21
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** The study was prematurely ended due to the modification of study requirements by the US Food and Drug Administration and the European Medicines Agency
- **Last updated:** 2019-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02688764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02688764, "A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02688764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*